Fate Therapeutics, Inc. (NASDAQ:FATE) – Analysts at Wedbush lifted their Q3 2017 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report issued on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, up from their previous estimate of ($0.26). Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. Wedbush also issued estimates for Fate Therapeutics’ Q4 2017 earnings at ($0.25) EPS, FY2017 earnings at ($0.97) EPS, Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.01) EPS, FY2019 earnings at ($0.68) EPS, FY2020 earnings at $0.14 EPS and FY2021 earnings at $2.38 EPS.

Several other research analysts have also recently commented on FATE. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a report on Thursday. ValuEngine cut shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 7th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $6.30.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/18/fate-therapeutics-inc-fate-forecasted-to-post-q3-2017-earnings-of-0-24-per-share.html.

Fate Therapeutics (FATE) opened at 3.02 on Thursday. Fate Therapeutics has a 12 month low of $1.80 and a 12 month high of $5.68. The firm’s market cap is $125.07 million. The company’s 50-day moving average is $3.04 and its 200 day moving average is $3.69.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative net margin of 887.68% and a negative return on equity of 67.01%.

Hedge funds have recently bought and sold shares of the company. Creative Planning boosted its stake in Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6,000 shares in the last quarter. KCG Holdings Inc. boosted its stake in Fate Therapeutics by 7.8% in the first quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,764 shares in the last quarter. New York State Common Retirement Fund bought a new stake in Fate Therapeutics during the second quarter valued at approximately $131,000. Rhumbline Advisers bought a new stake in Fate Therapeutics during the second quarter valued at approximately $133,000. Finally, Driehaus Capital Management LLC bought a new stake in Fate Therapeutics during the first quarter valued at approximately $145,000. Institutional investors and hedge funds own 61.15% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.